Levodopa is the gold standard for Parkinson’s disease treatment, but its short half-life leads to wearing-off periods at night and early morning.
OFF-periods result in a loss of motor function, affecting up to 60% of Parkinson’s patients, who suffer from early morning motor complications.
thus, current treatments fail to address this significant unmet need.

Morning akinesia is a common symptom among Parkinson’s patients, and its resolution remains a high unmet medical need.
Differentiated Characteristics from Existing Levodopa Formulations : Designed to deliver the drug at the time patients need symptom relief
The Phase 1b top-line results successfully demonstrated the drug's safety and tolerability, and the company is currently preparing for the Phase 2 clinical trial.
Significant global commercialization opportunity in the rapidly growing Parkinson’s disease market